Members Login
Channels
Special Offers & Promotions
Ubichem Research Acquisition to Enable Further Growth of Pharma Services Business
publication date: Jul 19, 2011
|
author/source: Ubichem Research Ltd.
The majority
share of Ubichem Research Ltd, a leading provider of chemistry services to the
drug development sector, through Ubichem Pharma
Services, has been acquired by financial investment company Lochlomond
Holding Limited, owned by Marton Szoke, and is now independent of Ubichem Plc
in the UK. The remaining minority share of Ubichem Research remains in the
ownership of Mr. József Répási, Managing Director of Ubichem Research Ltd.
József Répási commented: "It is a very exciting time for Ubichem Pharma Services. We have come a long way since Ubichem Research was founded in 1996, and this step will facilitate ambitious plans for further growth of our business, and enable us to provide an even better service to our customers."
Ubichem Pharma Services will continue to support the drug development programs of its pharma and biotech clients worldwide, from discovery through the clinic. Expertise in heterocyclic chemistry has enabled a catalogue of functionalised building blocks for use in medicinal chemistry projects to grow significantly over the last year. An experienced team of chemists offer custom synthesis and lead optimisation services, backed up by good in-house analytical capabilities. A strong focus on process R&D enables smooth scale-up in manufacturing APIs and intermediates. Recent regulatory approval for the supply of cGMP radiolabelled Active Pharmaceutical Ingredients (APIs) built on the approval obtained previously for the commercial supply of cGMP APIs.
József Répási commented: "It is a very exciting time for Ubichem Pharma Services. We have come a long way since Ubichem Research was founded in 1996, and this step will facilitate ambitious plans for further growth of our business, and enable us to provide an even better service to our customers."
Ubichem Pharma Services will continue to support the drug development programs of its pharma and biotech clients worldwide, from discovery through the clinic. Expertise in heterocyclic chemistry has enabled a catalogue of functionalised building blocks for use in medicinal chemistry projects to grow significantly over the last year. An experienced team of chemists offer custom synthesis and lead optimisation services, backed up by good in-house analytical capabilities. A strong focus on process R&D enables smooth scale-up in manufacturing APIs and intermediates. Recent regulatory approval for the supply of cGMP radiolabelled Active Pharmaceutical Ingredients (APIs) built on the approval obtained previously for the commercial supply of cGMP APIs.
Media Partners